The ARTEMIS-IPF study is for people who have been diagnosed with IPF and are between 40 and 80 years of age. People who have been diagnosed early in the disease may be more responsive to treatment. This is a randomised study (which means the participants will be selected by chance (like flipping a coin) to receive one of two treatments (ambrisentan or placebo). This is a double-blind study which means participants and their study doctor won’t know what treatment they are assigned to receive. Participants will have 2 out of 3 chances to receive ambrisentan, or 1 out of 3 chances to receive placebo (which is a tablet that looks like the active medicine but contains no active medicine). Taking part in the study could be up to 3 years depending on how long it takes to enroll and observe study events. After randomisation, visits take place every 3 months. Laboratory visits occur every month.
ARTEMIS-IPF: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel-Group, Event Driven Study to Evaluate the Efficacy and Safety of Ambrisentan in Subjects With Early Idiopathic Pulmonary Fibrosis (IPF)
- Idiopathic pulmonary fibrosis
Treatment, Randomised, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Primary outcome measures
- Time to death or disease (IPF) progression.
[ Time Frame: Event driven, up to 3 years ]
[ Designated as safety issue: No ]
Secondary outcome measures
- Proportion of subjects with disease progression or death at 48 weeks
[ Time Frame: 1 year from enrollment ]
[ Designated as safety issue: No ]
Study arms and assigned interventions
- Ambrisentan: Active Comparator Subjects will be randomized in a 2:1 ratio to receive Ambrisentan Drug: ambrisentan or sugar pill
- Ambrisentan 5mg or 10 mg tablet, or sugar pill (placebo) taken once a day, by mouth for the duration of the trial.
- Placebo: Placebo Comparator Subjects will be randomized in a 2:1 ratio to receive active drug versus sugar pill (placebo)
- Drug: ambrisentan or sugar pill Ambrisentan 5mg or 10 mg tablet, or sugar pill (placebo) taken once a day, by mouth for the duration of the trial.
December 2008 – December 2012
Eligibility & Criteria
- Ages eligible for study: 40 years to 80 years
- Genders eligible for study: Both
- Accepts healthy volunteers: No
- Diagnosis of IPF
- Honeycombing on HRCT scan of less than or equal to 5%
- Willing and able to have 2 right heart catheterisations performed
- Willing to have monthly lab tests
- Able to perform the 6 minute walk test
- Must meet lung function requirements
- Normal liver function tests
- No restrictive lung disease (other than IPF)
- No obstructive lung disease
- No recent or active respiratory exacerbations
- No recent hospitalization for an IPF exacerbation
- No recent history of alcohol abuse
- Not pregnant, breast-feeding and willing to follow contraceptive measures per protocol if applicable
- Chronic sildenafil (or same drug class) use for pulmonary hypertension
- Chronic treatment with certain medications for IPF within 30 days of randomisation
- No other serious medical conditions
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.